Clinical Trial Update: 24-week Open-label Extension Study Evaluating PXT00864 Effect in Mild AD Patients Further to PLEODIAL-I Completion [Phase 2]

View source ↗

Summary

Pharnext reports the completion of a 24-week open-label extension study evaluating PXT00864 in mild Alzheimer's disease after completion of PLEODIAL-I (Phase 2)…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• PXT00864

Snippet

Sponsor: Pharnext S.C.A. | Conditions: Alzheimer Disease | Phase 2 | Status: COMPLETED